Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Open-label, 2-way Crossover Relative Bioavailability and Safety Trial With Two Differing Strength Tablets (3 x 5 mg vs. 1 x 15 mg) of Sublingually Administered Org 5222 in Subjects With Schizophrenia or Schizoaffective Disorder.

NCT01101464 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT01101464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01101464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Open-label, 2-way Crossover Relative Bioavailability and Safety Trial With Two Differing Strength Tablets (3 x 5 mg vs. 1 x 15 mg) of Sublingually Administered Org 5222 in Subjects With Schizophrenia or Schizoaffective Disorder.
Lead sponsor
Organon and Co
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2002
Completion date
December 31, 2002
Enrollment
8 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia